431886-96-3

Basic information

• Product Name: 6-chloro-7-Methoxy-9H-pyrido[3,4-b]indol-8-aMine
• Synonyms: 6-chloro-7-Methoxy-9H-pyrido[3,4-b]indol-8-aMine;6-chloro-7-Methoxy-9H-β-carbolin-8-ylaMine
• CAS NO: 431886-96-3
• Molecular Formula: C12H10ClN3O
• Molecular Weight: 247.6803
• Mol File: 431886-96-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloro-7-Methoxy-9H-pyrido[3,4-b]indol-8-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-7-Methoxy-9H-pyrido[3,4-b]indol-8-aMine(431886-96-3)
• EPA Substance Registry System: 6-chloro-7-Methoxy-9H-pyrido[3,4-b]indol-8-aMine(431886-96-3)

Safety Data

• Hazardous Substances Data: 431886-96-3(Hazardous Substances Data)

Usage

Derivative of

Harmine

Therapeutic Properties

Anti-cancer:
Inhibits growth of cancer cells in various tumors (breast, lung, prostate).
Anti-inflammatory:
Reduces production of inflammatory cytokines.
Neuroprotective:
Potential treatment for neurodegenerative diseases.

Specific Effects

Anti-cancer Activity:
Effective against breast, lung, and prostate cancers.
Anti-inflammatory Effects:
Reduces inflammatory cytokine production.
Neuroprotective Potential:
May help protect against loss of brain cells.

Overall Potential

Promising therapeutic agent for various diseases and conditions.

Upstream product

• 431897-30-2 6-chloro-7-methoxy-8-nitro-9H-β-carboline 

Downstream Products

• 783348-36-7 N-(6-chloro-7-methoxy-9H-β-carbolin-8-yl)-2-methyl-nicotinamide 

Relevant articles and documents

Beta-carbolines useful for treating inflammatory disease

This invention provides beta-carboline compounds of formula III-A-aa: wherein Q, G, R1, R2, R3, and R6b are as described in the specification. The compounds are useful for treating diseases such as inflammatory diseases and cancer.

BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE

This invention provides beta-carboline compounds of formula (I) wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R1, R2 and R3 are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2 mediated diseases such as inflammatory diseases and cancer.

Substituted beta-carbolines

Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IκB kinase is involved.